



ARCHIVOS DE Bronconeumología

www.archbronconeumol.org



Original Article

Impact of OLD/Emphysema in LC Mortality Risk in Screening Programs: An Analysis of NLST and P-IELCAP

Jessica González^{a,b,*}, Luis M. Seijo^{b,c}, Juan P. de-Torres^{d,e}, Iván D. Benítez^{a,b},
María del Mar Ocón^d, Ferran Barbé^{a,b}, Juan P. Wisnivesky^f, Javier J. Zulueta^g

^a Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain

^b CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain

^c Pulmonary Department, Clínica Universidad de Navarra, Madrid, Spain

^d Pulmonary Department, Clínica Universidad de Navarra, Pamplona, Spain

^e Navarra's Health Research Institute (IDISNA), Pamplona, Spain

^f Divisions of General Internal Medicine and Pulmonary and Critical Care Medicine, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA

^g Pulmonary, Critical Care and Sleep Division, Mount Sinai Morningside Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA

ARTICLE INFO

Article history:

Received 6 March 2024

Accepted 14 May 2024

Available online xxx

Keywords:

COPD

Emphysema

Lung cancer screening

ABSTRACT

Introduction: The impact of obstructive lung disease (OLD) and emphysema on lung cancer (LC) mortality in patients undergoing LC screening is controversial.

Methods: Patients with spirometry and LC diagnosed within the first three rounds of screening were selected from the National Lung Screening Trial (NLST) and from the Pamplona International Early Lung Cancer Detection Program (P-IELCAP). Medical and demographic data, tumor characteristics, comorbidities and presence of emphysema were collected. The effect of OLD and emphysema on the risk of overall survival was assessed using unadjusted and adjusted Cox models, competing risk regression analysis, and propensity score matching.

Results: Data from 353 patients with LC, including 291 with OLD and/or emphysema and 62 with neither, were analyzed. The median age was 67.3 years-old and 56.1% met OLD criteria, predominantly mild (1: 28.3%, 2: 65.2%). Emphysema was present in 69.4% of the patients. Patients with OLD and/or emphysema had worse survival on univariate analysis (HR: 1.40; 95% CI: 0.86–2.31; $p = 0.179$). However, after adjusting for LC stage, age, and sex, the HR was 1.02 (95% CI: 0.61–1.70; $p = 0.952$). Specific LC survival between both groups showed an adjusted HR of 0.90 (95% CI: 0.47–1.72; $p = 0.76$). Propensity score matching found no statistically significant difference in overall survival (HR: 1.03; 95% CI: 0.59–1.9; $p = 0.929$).

Conclusion: The survival of LC patients diagnosed in the context of screening is not negatively impacted by the coexistence of mild OLD and/or emphysema.

© 2024 SEPAR. Published by Elsevier España, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Introduction

Lung cancer (LC) is the leading cause of cancer-related mortality worldwide.¹ Smoking is not only the primary risk factor for LC, but increases the risk of other respiratory diseases such as chronic obstructive pulmonary disease (COPD) and emphysema,² which in turn are strongly associated with the development of LC.^{3–7} Lung cancer screening is effective in reducing LC mortality,^{8–10} but there is a growing concern about the risks of screening patients with coexisting chronic lung disease.¹¹

The impact of COPD and emphysema on mortality in patients with LC remains controversial. Some studies have reported a worse prognosis attributed to post-treatment complications.^{12–14} However, improvements in bronchodilator treatment,^{13,15} physical therapy,¹⁶ and even advances in thoracic surgery and radiation therapy¹⁷ have challenged these findings in other studies. Moreover, treatment of early-stage LC in patients with coexisting COPD or emphysema may even result in spirometric improvements due to a reduction of lung volume.^{18–22}

Evidence regarding the impact of these pulmonary diseases on LC mortality in lung cancer screening programs is limited, and generally based on secondary analyses of cohorts with limited sample size and/or underpowered statistical analysis.²³ Due to the large proportion of patients with COPD and/or emphysema participating

* Corresponding author.

E-mail address: jgonzalezgutierrez88@gmail.com (J. González).

<https://doi.org/10.1016/j.arbres.2024.05.009>

0300-2896/© 2024 SEPAR. Published by Elsevier España, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

in these programs,²⁴ there is a need for larger studies focused on the impact of these respiratory comorbidities on survival of patients who are diagnosed with LC in the context of screening. Our study focuses on patients who were screened for LC but also underwent lung function testing from the ACRIN sub-cohort of the National Lung Screening Trial (NLST) and the Pamplona (Spain) sub-cohort of the International Early Lung Action Program (P-IELCAP). To avoid confounding factors and to increase precision, competing risks and propensity score matching analysis were used.

Methods

Trials Oversight

The National Lung Screening Trial (NLST) was a randomized trial comparing screening for lung cancer using LDCT with chest radiography. Participants were invited to undergo three screening rounds (T0, T1, T2) at 1-year intervals. The NLST enrolled participants between August 2002 and September 2007, and followed through December 2009. The NLST was approved by the institutional review board at each of the 33 participating medical institutions. Details about the study protocol, participant follow-up, medical-record abstraction, LDCT and lung function test characteristics are detailed in the original study.⁹

The Pamplona sub-cohort of the International Early Lung Cancer Action Program (P-IELCAP) is a consolidated lung cancer screening program that began in 2000 in Spain, and has screened more than 5000 individuals at risk for LC. The ongoing program offers ongoing annual LDCT and pulmonary function testing for all participants. Details of the protocol have been described previously.²⁵

Study Population

The NLST included current or former smokers (abstinence <15 years) with ages ranging from 55 to 74 years at the time of randomization, and a smoking history of at least 30 pack-years. P-IELCAP enrolled adults ≥ 40 years-old, with a smoking history of more than 10 pack-years.

A total of 53,452 individuals were enrolled in the NLST and 26,722 were randomly assigned to screening with low-dose computed tomography (LDCT). LC was diagnosed in 1089 individuals in the LDCT arm, of which 790 were found during the three rounds of screening (T0–T2). Screening by the American College of Radiology Imaging Network (ACRIN cohort), included spirometry testing at enrollment.²⁶ For the purpose of our study, we selected participants who were diagnosed with LC during the first three rounds of screening and had spirometry performed during the study, yielding a final cohort of 235 NLST patients.

In the P-IELCAP cohort, a total of 126 patients were diagnosed with LC between February 2001 and September 2021. For the purpose of this study, we selected 118 patients who had valid lung function testing.

Population Characteristics

Demographic characteristics and comorbidities were recorded at baseline in both cohorts. The presence of emphysema was visually determined on the LDCT. Prebronchodilator spirometry was performed at baseline and OLD was defined by the presence and severity of airway limitation based on Global Initiative for Chronic Obstructive Lung Disease criteria ($FEV_1/FVC < 70$, grades 1–4).²⁷ Patients were classified into two groups, i.e., patients with OLD and/or emphysema (OLD/emphysema), and patients with normal lung function and no emphysema on LDCT. The latter group were classified as “smokers without lung disease.”

Tumor characteristics were also recorded for all participants with lung cancer. Disease stage was determined according to the seventh edition of the Cancer Staging Manual of the American Joint Committee on Cancer, and histology was classified according to the *International Classification of Diseases for Oncology, 3rd Edition* (ICD-O-3).²⁸

Statistics

Descriptive statistics were used to summarize the characteristics of the study population. Absolute and relative frequencies were used for qualitative data. The means (SD) and medians (25th–75th percentile) were estimated for quantitative variables with normal and non-normal distributions, respectively. Normal distributions were assessed by the Shapiro–Wilk test. Baseline data were compared between study groups (healthy smokers or COPD and/or emphysema) using the Wilcoxon signed-rank test for continuous variables and the chi-square test (or Fisher's exact test when the expected frequencies were less than five in some cells) for qualitative variables. Furthermore, baseline data were compared between disaggregated groups (smokers without lung disease, OLD and emphysema) using ANOVA (or Kruskal–Wallis test for variables with non-normal distribution) for continuous variables. The effect of the presence of OLD and/or emphysema on the risk of overall mortality was assessed using unadjusted and adjusted Cox model. Age, sex and TNM stage were included in the model as confounding factors. Additionally, risk of cancer mortality was evaluated using Fine–Gray's model considering mortality from other causes as competing risk.²⁹ The same survival analysis was performed for disaggregated study groups. The dose–response relationship between pulmonary function parameters (forced expiratory volume in the 1st second [FEV_1] and forced vital capacity [FVC]) with overall mortality risk in OLD population was assessed using Cox proportional hazard model adjusted for confounding factors (age, sex and cancer stage). Time elapsed from cancer diagnosis to event was used in survival analyses. Finally, sensitivity analysis with the same survival analysis previously described was applied in a population matched for sociodemographic and clinical characteristics. The matching process, using a 2:1 ratio, was performed using a nearest neighbors matching with a propensity score caliper distance of 0.1 to select matched patients between groups. Matching processes were performed to enable comparability between study groups. A standardized mean difference (SMD) between groups of less than 0.1 was defined as optimal quality match. Matching processes included age, sex, TNM stage. R statistical software, version 4.0.1 (R Project for Statistical Computing) was used for all analyses.

Results

Baseline Clinical Characteristics, Lung Function and LC Stage

The characteristics of the study population are shown in [Table 1](#). A total of 353 patients with LC from both cohorts were included in the analysis, of whom 291 had OLD and/or emphysema and 62 were classified as “smokers without lung disease”. The median ($p_{25}; p_{75}$) age was 67.3 years (62.8;72.5). The cohort was predominantly male (66%) and heart disease (13.9%), chronic bronchitis (12.5%) and diabetes (10.5%) were the most common comorbidities. More than a half of the population (56.1%) met OLD criteria, with a median FEV_1 of 65.5% (60.2;80.8). These patients had predominantly mild severity of airway obstruction (1: 28.3%, 2: 65.2%), with only 6.5% in stage 3, and none in stage 4. Emphysema was present in 69.4% of the entire cohort. Patients in the OLD/emphysema group were more likely males (70.8% vs 43.5%; $p < 0.001$) with worse lung function (median of FEV_1 of 77% (63;94) vs 87% (74.2;97.8); $p < 0.001$).

Table 1
Sociodemographic and Clinical Characteristics According to Presence of OLD and/or Emphysema.

	Global n = 353 Median [p25;p75] or n (%)	Smokers Without Lung Disease n = 62 Median [p25;p75] or n (%)	OLD and/or Emphysema n = 291 Median [p25;p75] or n (%)	p Value
<i>Sociodemographic</i>				
Age, years	67.3 [62.8;72.5]	68.0 [62.9;71.9]	67.3 [62.8;72.7]	0.874
Sex, male	233 (66.0%)	27 (43.5%)	206 (70.8%)	<0.001
Pack-years	52.0 [40.0;75.0]	50.1 [39.3;74.2]	52.5 [40.0;75.0]	0.969
<i>Comorbidities</i>				
Diabetes	37 (10.5%)	8 (12.9%)	29 (9.97%)	0.647
Heart disease	49 (13.9%)	9 (14.5%)	40 (13.7%)	1.000
Stroke	12 (3.40%)	2 (3.23%)	10 (3.44%)	1.000
Chronic bronchitis	44 (12.5%)	9 (14.5%)	35 (12.1%)	0.758
Asthma	16 (4.56%)	2 (3.23%)	14 (4.84%)	0.747
<i>CT findings</i>				
Emphysema	245 (69.4%)	0 (0.00%)	245 (84.2%)	<0.001
<i>Pulmonary function</i>				
OLD	198 (56.1%)	0 (0.00%)	198 (68.0%)	<0.001
FEV ₁ , %	79.0 [64.0;95.0]	87.0 [74.2;97.8]	77.0 [63.0;94.0]	0.001
FVC, %	90.0 [76.0;105]	86.0 [78.0;98.8]	91.0 [75.0;107]	0.279
FEV ₁ to FVC ratio	67.6 [59.7;74.2]	76.5 [73.2;79.9]	65.7 [57.0;71.4]	<0.001
<i>Lung cancer stage</i>				
Stage I	200 (56.7%)	40 (64.5%)	160 (55.0%)	0.165
Stage II	18 (5.10%)	4 (6.45%)	14 (4.81%)	
Stage III	62 (17.6%)	8 (12.9%)	54 (18.6%)	
Stage IV	55 (15.6%)	10 (16.1%)	45 (15.5%)	
Not specified	18 (5.10%)	0 (0.00%)	18 (6.19%)	

Abbreviations: OLD, obstructive lung disease; CT, computerized tomography; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity.

No differences in other comorbidities between the groups were seen (Table 1). When compared to smokers without lung disease, LC in the OLD/emphysema group tended to be diagnosed in more advanced stages (29% vs 36%, respectively, diagnosed in stages 3–4), but the difference did not reach statistical significance (Table 1). Sociodemographic and clinical characteristics stratified by lung function and the presence of emphysema (three groups) are shown in Table S1.

Survival Analysis for Overall and Cancer Mortality According to Study Groups

Fig. 1 and model 1 of Table S2 show unadjusted survival analysis of mortality and specific LC survival between the groups of smokers without lung disease and COPD/emphysema. Individuals in the OLD/emphysema group had the worst survival rate with a HR (95% CI) of 1.40 (0.86–2.31; $p=0.179$) in Cox model, and a SHR of 1.26 (0.73–2.18; $p=0.41$) in competing risk regression. However, no difference was observed between groups when adjusting for the most important confounding factors (age, sex and LC stage) in Cox and competing risk regression with HRs of 1.02 (95% CI: 0.61–1.70; $p=0.952$) and 0.90 (0.77–1.72; $p=0.76$), respectively (Fig. 2 and model 1 of Table S2). Furthermore, in patients with OLD we did not observe a dose–response relationship after adjusting for confounding factors between pulmonary function (FEV₁ and FVC) and overall survival (Fig. S1). Similar results were obtained when the unadjusted and adjusted survival models were performed in the OLD and emphysema groups separately (model 2 of Table S2 and Figs. S2–S4).

Sensitivity Analysis Using Matched Populations

To corroborate these results, propensity score matching was used to enable comparisons between study groups. After the matching process (1:2, including: age, sex and LC stage), a total of 60 smokers without lung disease were matched with 121 patients with OLD and/or emphysema. Sociodemographic and clinical characteristics of this matched population are shown in Table S3. After

the matching process, the groups showed covariate balance in confounding factors, highlighting the importance of these analyses to make the groups more homogeneous and comparable (Fig. S5-A). Finally, the Kaplan–Meier curves according to the study groups showed no statistically significant differences in overall survival with a HR of 1.03 (95% CI: 0.59–1.9; $p=0.929$; Fig. S5-B).

Discussion

Our results show that LC mortality in the context of screening is not influenced by the presence of mild OLD and/or emphysema as demonstrated by competing risk and propensity score matching of two lung cancer screening cohorts (NLST and P-IELCAP).

These results assuage concerns regarding the impact of OLD and emphysema on the risks and benefits of lung cancer screening.^{11,30} Whether more severe forms of OLD or emphysema can affect screening outcomes has yet to be determined, since most individuals offered screening have mild disease given the need for being candidates for resection.^{23,31,32} This is crucial, mounting evidence shows that LC is one of the most important causes of death in patients with early stages of COPD.^{33–35} Previous studies have shown that in patients undergoing screening, the presence of COPD doubles the incidence of LC, reduces the risk of overdiagnosis, and is associated with a more favorable stage shift and a reduction in mortality.^{23,26} Our results, with a fairly larger number of LC cases and using robust statistical analyses, strengthen these findings by focusing on patients with LC diagnosed in the context of annual LC screening.

Several previous studies point to COPD and emphysema as contributing factors to worse overall survival and disease-free survival (DFS) in patients with LC.^{12–14} Most of them were small retrospective cohorts of patients with resected LC.^{12–14} However, the mild COPD group in these studies showed similar DFS compared to the non-COPD group¹⁴ as shown in our study. Additionally, a meta-analysis of 27 studies¹³ revealed that the presence of COPD and emphysema was associated with poorer overall survival (HR: 1.17; 95% CI: 1.10–1.25 and HR: 1.66; 95% CI: 1.25–2.22, respectively). Nevertheless, some aspects should be considered before draw-




Fig. 1. Unadjusted survival analysis for overall mortality and cancer mortality according to study groups. (A) The Kaplan–Meier curve and unadjusted/adjusted HR (95% CI) estimated using Cox regression model. Age, sex and TNM stage were included as adjustment variables. (B) Cumulative Incidence curves of events for competing risks analysis and unadjusted/adjusted subdistribution hazard (95% CI) for cancer mortality. *Abbreviations:* SWLD, smokers without lung disease; OLD, obstructive lung disease; HR, hazard ratio; SHR, subdistribution hazard ratio; CI, confidence interval.




Fig. 2. Adjusted survival models according to the presence of OLD and/or emphysema. (A) Hazard ratios (95% CI) of multivariable Cox model. (B) Adjusted survival curves for Cox proportional hazards model according to the presence of OLD and/or emphysema. *Abbreviations:* SWLD, smokers without lung disease; OLD, obstructive lung disease; HR, hazard ratio; SHR, subdistribution hazard ratio; CI, confidence interval.

ing conclusions, such as the high heterogeneity found between the studies ($I_2 = 78\%$) and the fact that COPD diagnosis was self-recorded or identified from the medical record without spirometry in more than a half of the cohorts. More importantly, none of these studies were performed in the context of lung cancer screening programs. The limited research conducted within screening contexts indicates a higher incidence and mortality rate of lung cancer (LC), as well as a greater frequency of diagnoses at advanced stages in patients with obstructive lung disease (OLD) and/or emphysema.^{36,37} The fact repeatedly observed in these studies (and in ours) that patients with these underlying lung diseases have a more aggressive LC^{12,26} appears not to affect survival in mild OLD patients undergoing lung cancer screening programs.

As many as 40–66% of LCs detected in established lung cancer screening programs and screening trials occur in individuals with COPD and/or emphysema,^{24,38,39} our study demonstrates that

these patients do not exhibit worse survival despite underlying pulmonary comorbidities. As mentioned before, tumor stage remains the only variable consistently associated with a worse prognosis. Additionally, it has been observed that the treatment of early LC stages in patients with COPD and emphysema can minimize pulmonary function loss after surgery or sometimes even improve it. This occurs more often in patients with emphysema when the LC is located in an emphysematous area (as it usually is) resulting in lung volume reduction.^{18–22} For these reasons, patients with mild COPD and emphysema should not be excluded from screening programs. There is an increasing general recognition of this fact, even as an implicit recommendation in the new GOLD guidelines for the management of patients with COPD.²

This study has several limitations. Firstly, it is a retrospective review of a prospective trial, with a sub-selection of individuals due to the lack of lung function on the entire cohort. However, the

included cohort was fairly large and had been assigned to have lung function tests a priori, which limits bias due to selection. Secondly, we labeled patients with irreversible airflow obstruction and OLD and not COPD because the definition of the latter should include symptoms and we do not have access to that information. For this reason, these findings may not be generalizable to all patients with COPD. Moreover, lung function is not expressed using currently accepted Z-scores. Thirdly, only prebronchodilator spirometry lung function was done and this is known to overestimate the prevalence of "COPD".⁴⁰ It is possible that a more rigorous selection of patients with COPD, would have resulted in a significant influence of the presence of OLD on LC specific survival. Finally, emphysema was determined visually by radiologists and no quantification or grading of the severity is available. A validation of the diagnosis of emphysema (or its quantification by software) in the cohort has not been performed and the effect of different grades of severity cannot be analyzed.

In conclusion, the outcomes of patients with LC diagnosed in the context of lung cancer screening with an annual LDCT is not affected by the presence of mild OLD and/or emphysema. In clinical practice, these patients should be considered candidates for lung cancer screening programs.

Role of the Funding Source

Funding agencies were not involved in study design, data collection nor analysis, decision to publish, or preparation of the manuscript.

Funding

This work was supported in part by a grant [RD12/0036/0062 and RD12/0036/0040] from Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, the Spanish Ministry of Economy and Competitiveness and European Regional Development Fund "Una manera de hacer Europa." It was also supported by grants PI04/2404, PI07/0792, PI10/01652, and PI11/01626 from the Instituto de Salud Carlos III, Ministry of Economy and Competitiveness, Government of Spain.

Authors' Contributions

J.J. Zulueta is the guarantor of the paper, taking responsibility for the integrity of the work as a whole, from inception to published article. J.G, J.PdT, IdB, LMS, JPW, FB, and JJZ were responsible for conception and design, analysis and interpretation, and drafting of the manuscript for important intellectual content.

Conflict of Interests

LMS has received consultancy fees for participating in advisory boards for Sabartech, the Lung Ambition Alliance, and Serum; he also received fees for speaking activities from Astra Zeneca, Roche, and Merck, Sharp & Dohme Corporation.

JJZ has received consultancy fees for participating in advisory boards for Median Technologies and American Heart Technologies; he is a shareholder of VisionGate, Inc.

JPW has received honorarium from PPD, Banoock, Sanofi and grants from Sanofi, Regeneron, Axella and Arlnold Consultants.

None declared (J.G, J.PdT, IdB, MMO, FB).

Appendix A. Supplementary Data

Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.arbres.2024.05.009](https://doi.org/10.1016/j.arbres.2024.05.009).

References

1. Ebrahimi H, Aryan Z, Saeedi Moghaddam S, Bisignano C, Rezaei S, Pishgar F, et al. Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Respir Med.* 2021;9:1030–49.
2. Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. *Eur Respir J.* 2023;61(4):2300239. <http://dx.doi.org/10.1183/13993003.00239-2023>.
3. Wilson DO, Weissfeld JL, Balkan A, Schragin JG, Fuhrman CR, Fisher SN, et al. Association of radiographic emphysema and airflow obstruction with lung cancer. *Am J Respir Crit Care Med.* 2008;178(7):738–44. <http://dx.doi.org/10.1164/rccm.200803-435OC>.
4. de Torres JP, Bastarrika G, Wisnivesky JP, Alcaide AB, Campo A, Seijo LM, et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. *Chest.* 2007;132(6):1932–8. <http://dx.doi.org/10.1378/chest.07-1490>.
5. Sanchez-Salcedo P, Wilson DO, de-Torres JP, Weissfeld JL, Berto J, Campo A, et al. Improving selection criteria for lung cancer screening: the potential role of emphysema. *Am J Respir Crit Care Med.* 2015;191:924–31.
6. Yong PC, Sigel K, De-Torres JP, Mhango G, Kale M, Kong CY, et al. The effect of radiographic emphysema in assessing lung cancer risk. *Thorax.* 2019;74:858–64.
7. de Torres JP, Marín JM, Casanova C, Cote C, Carrizo S, Cordoba-Lanus E, et al. Lung cancer in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2011;184:913–9.
8. International Early Lung Cancer Action Program Investigators; Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, et al. Survival of patients with stage I lung cancer detected on CT screening. *N Engl J Med.* 2006;355(17):1763–71. <http://dx.doi.org/10.1056/NEJMoa060476>.
9. National Lung Screening Trial Research Team; Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med.* 2011;365(5):395–409. <http://dx.doi.org/10.1056/NEJMoa1102873>.
10. de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. *N Engl J Med.* 2020;382:503–13.
11. de-Torres JP, Wisnivesky JP. Lung cancer screening in patients with chronic obstructive pulmonary disease: do the benefits outweigh the risks? *Arch Bronconeumol.* 2021;57:679–80.
12. Zhai R, Yu X, Shafer A, Wain JC, Christiani DC. The impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resection. *Chest.* 2014;145:346–53.
13. Gao Y-H, Guan W-J, Liu Q, Wang H-Q, Zhu Y-N, Chen R-C, et al. Impact of COPD and emphysema on survival of patients with lung cancer: a meta-analysis of observational studies. *Respirology.* 2016;21:269–79.
14. Qiang G, Liang C, Xiao F, Yu Q, Wen H, Song Z, et al. Impact of chronic obstructive pulmonary disease on postoperative recurrence in patients with resected non-small-cell lung cancer. *Int J COPD.* 2015;11:43–9.
15. Shin SH, Shin S, Im Y, Lee G, Jeong B-H, Lee K, et al. Effect of perioperative bronchodilator therapy on postoperative pulmonary function among lung cancer patients with COPD. *Sci Rep.* 2021;11:8359.
16. Wang L, Yu M, Ma Y, Tian R, Wang X. Effect of pulmonary rehabilitation on postoperative clinical status in patients with lung cancer and chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Evid Based Complement Alternat Med.* 2022;2022:4133237.
17. Doi H, Nakamatsu K, Nishimura Y. Stereotactic body radiotherapy in patients with chronic obstructive pulmonary disease and interstitial pneumonia: a review. *Int J Clin Oncol.* 2019;24:899–909.
18. Kang N, Shin SH, Noh JM, Kang D, Kim H, Kwon OJ, et al. Treatment modality and outcomes among early-stage non-small cell lung cancer patients with COPD: a cohort study. *J Thorac Dis.* 2020;12:4651–60.
19. Brunelli A, Charloux A, Bolliger CT, Rocco G, Sculier J-P, Varela G, et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). *Eur Respir J.* 2009;34:17–41.
20. Choong CK, Mahesh B, Patterson GA, Cooper JD. Concomitant lung cancer resection and lung volume reduction surgery. *Thorac Surg Clin.* 2009;19:209–16.
21. Caviezel C, von Rotz J, Schneider D, Inci I, Hillinger S, Opitz I, et al. Improved postoperative lung function after sublobar resection of non-small-cell lung cancer combined with lung volume reduction surgery in patients with advanced emphysema. *J Thorac Dis.* 2018;10:S2704–10.
22. Kushibe K, Takahama M, Tojo T, Kawaguchi T, Kimura M, Taniguchi S. Assessment of pulmonary function after lobectomy for lung cancer – upper lobectomy might have the same effect as lung volume reduction surgery. *Eur J Cardiothorac Surg.* 2006;29:886–90.
23. de-Torres JP, Wisnivesky JP, Bastarrika G, Wilson DO, Celli BR, Zulueta JJ. Exploring the impact of lung cancer screening on lung cancer mortality of smokers with obstructive lung disease: analysis of the NLST-ACRIN Cohort. *Arch Bronconeumol.* 2021;57:36–41.
24. Sanchez-Salcedo P, Wilson DO, De-Torres JP, Weissfeld JL, Berto J, Campo A, et al. Improving selection criteria for lung cancer screening: the potential role of emphysema. *Am J Respir Crit Care Med.* 2015;191(8):924–31. <http://dx.doi.org/10.1164/rccm.201410-1848OC>.

25. Bastarrika G, García-Velloso MJ, Lozano MD, Montes U, Torre W, Spiteri N, et al. Early lung cancer detection using spiral computed tomography and positron emission tomography. *Am J Respir Crit Care Med.* 2005;171:1378–83.
26. Young RP, Duan F, Chiles C, Hopkins RJ, Gamble GD, Greco EM, et al. Airflow limitation and histology shift in the National Lung Screening Trial. The NLST-ACRIN Cohort Substudy. *Am J Respir Crit Care Med.* 2015;192:1060–7.
27. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global Strategy for the Diagnosis Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. *Am J Respir Crit Care Med.* 2017;195:557–82.
28. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin LH, Parkin DM, et al. International classification of diseases for oncology. 3rd ed. World Health Organization; 2000 <https://apps.who.int/iris/handle/10665/42344>
29. Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. *Circulation.* 2016;133:601–9.
30. Rivera MP, Tanner NT, Silvestri GA, Detterbeck FC, Tammemägi MC, Young RP, et al. Incorporating coexisting chronic illness into decisions about patient selection for lung cancer screening. An Official American Thoracic Society Research Statement. *Am J Respir Crit Care Med.* 2018;198:e3–13.
31. de-Torres JP, Wisnivesky JP, Bastarrika G, Wilson DO, Celli BR, Zulueta JJ. The prevalence of obstructive lung disease in a lung cancer screening cohort: analysis of the National Lung Screening Trial–American College of Radiology Image Network Cohort. *Ann Am Thorac Soc.* 2019;16:641–4.
32. Ruparel M, Quaife SL, Dickson JL, Horst C, Tisi S, Hall H, et al. Prevalence symptom burden, and underdiagnosis of chronic obstructive pulmonary disease in a lung cancer screening cohort. *Ann Am Thorac Soc.* 2020;17:869–78.
33. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. *Thorax.* 2007;62:411–5.
34. Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2009;180:948–55.
35. Labaki WW, Gu T, Murray S, Curtis JL, Wells JM, Bhatt SP, et al. Causes of and clinical features associated with death in tobacco cigarette users by lung function impairment. *Am J Respir Crit Care Med.* 2023;208(4):451–60. <http://dx.doi.org/10.1164/rccm.202210-1887OC>.
36. Labaki WW, Xia M, Murray S, Hatt CR, Al-Abcha A, Ferrera MC, et al. Quantitative emphysema on low-dose CT imaging of the chest and risk of lung cancer and airflow obstruction: an analysis of the National Lung Screening Trial. *Chest.* 2021;159:1812–20. <http://dx.doi.org/10.1016/j.chest.2020.12.004>.
37. Balbi M, Sabia F, Ledda RE, Milanese G, Ruggirello M, Silva M, et al. Automated coronary artery calcium and quantitative emphysema in lung cancer screening: association with mortality, lung cancer incidence, and airflow obstruction. *J Thorac Imaging.* 2023;38:W52–63. <http://dx.doi.org/10.1097/RTI.0000000000000698>.
38. Sanchez-Salcedo P, Berto J, De-Torres JP, Campo A, Alcaide AB, Bastarrika G, et al. Lung cancer screening: fourteen year experience of the Pamplona early detection program (P-IELCAP). *Arch Bronconeumol.* 2015;51:169–76.
39. Wilson DO, Weissfeld JL, Fuhrman CR, Fisher SN, Balogh P, Landreneau RJ, et al. The Pittsburgh Lung Screening Study (PLUSS): outcomes within 3 years of a first computed tomography scan. *Am J Respir Crit Care Med.* 2008;178:956–61.
40. Montes de Oca M, Tálamo C, Perez-Padilla R, Jardim JRB, Muiño A, Lopez MV, et al. Chronic obstructive pulmonary disease and body mass index in five Latin America cities: the PLATINO study. *Respir Med.* 2008;102(5):642–50. <http://dx.doi.org/10.1016/j.rmed.2007.12.025>.